The completion of the acquisition follows the approval of the competition authority on 20 April 2017. The Belmedis distribution business, the pre-wholesaling business Cophana and a majority stake in Sofiadis, an important buying group, will strengthen the market position of Celesio in Belgium.
Commenting on the acquisition, Brian S. Tyler, Chairman of the Management Board of Celesio AG, said: “By combining these two great companies we are adding value for our customers and for the country's pharmacists by improving our service capabilities and offerings in Belgium.” Brian Tyler added: “As a result of this transaction, we are becoming the partner of choice for manufacturers.”
More than 450 Belmedis and Cophana employees will join Celesio as part of the acquisition.
About the Celesio Group
Celesio is a leading international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sector. The proactive and preventive approach ensures that patients receive the products and support that they require for optimum care.
With strong brands and about 36,000 employees, the group is active in 13 European countries (thereof with own operations in ten countries; Celesio manages operations in two countries and participates in one country in a joint venture). Every day, the company serves over 2 million customers – at more than 2,150 pharmacies of its own, at about 300 managed pharmacies and at over 5,500 participants in the brand partnership schemes. With 109 wholesale branches in Europe, Celesio supplies more than 50,000 pharmacies and hospitals every day with up to 130,000 pharmaceutical products.
McKesson Corporation, San Francisco, USA, is the majority shareholder in Celesio AG. The company acquired more than 75 percent of Celesio AG shares in February 2014. McKesson is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology.